血管紧张素转换酶2研究进展

的基因印迹,把它和其他的发热感染性疾病区别开来。

[参考文献]

[1]󰀁PinnaGS,KafetzisDA,TselkasOI,eta.lKawasakidisease:anoverview[J].

CurrOpinInfectDis,2008,21(3):263󰀁270.

[2]󰀁NakamuraY,YashiiroM,UeharaR,eta.lIncreasingincidenceofKawasakidis󰀁

easeinJapan:nationwidesurvey[J].PediatrIntern,2008,50(3):287󰀁290.

[3]󰀁BurnsJC,GlodeMP.Kawasakisyndrome[J].Lance,t2004,364(433):533󰀁

544.

[4]󰀁WangCL,WuYT,LiuCA,eta.lKawasakidiseaseinfection,immunityandge󰀁

netics[J].PediatrInfectDisJ,2005,24(11):998󰀁1004.

[5]󰀁BurgnerD,HarndenA.Kawasakidisease:whatistheepidemiologytellingusa󰀁

bouttheetiology[J].InternJInfectDis,2005,9(3):185󰀁194.

[6]󰀁LeungDY,MeissnerHC,FultonDR,eta.lToxicshocksyndrometoxin󰀁secreting

staphlococcusaureusinKawasakisyndrome[J].Lancet,1993,342(8884):

1385󰀁1388.

[7]󰀁MatsubaraK,FukayaT.TheroleofsuperantigensofgroupAstreptococcusand

staphylococcusaureusinKawasakidisease[J].CurrOpinInfectDis,2007,20

(3):298󰀁303.

[8]󰀁MatsubaraK,FukayaT,MiwaK,eta.lDevelopmentofserumIgMantibodiesa󰀁

gainstsuperantigensofstaphylococcusaureusandstreptococcuspyogenesinKa󰀁

wasakidisease[J].ClinExpImmuno,l2006,143(3):427󰀁434.

[9]󰀁SuenagaT,SuzukiH,ShibutaS,eta.lDetectionofmultiplesuperantigengenes

instoolsofpatientswithKawasakidisease[J].JPediatr,2009,155(2):266󰀁

270.

[10]󰀁YamashiroY,NagataS,OhtsukaY,eta.lMicrobiologicstudiesonthesmallin󰀁

testineinKawasakidisease[J].PediatrRes,1996,39(4):622󰀁624.

[11]󰀁ChouCT,ChangJS,OoiSE,eta.lSerumanti󰀁YersiniaantibodyinChinesepa󰀁

tientswithKawasakidisease[J].ArchMedRes,2005,36(1):14󰀁18.

[12]󰀁TurkayS,OdemisE,KaradagA.Kawasakidiseaseonsetduringconcomitantin󰀁

fectiouswithvaricellazosterandEpstein󰀁Barrvirus[J].JNatMedAssoc,

2006,98(8):1350󰀁1352.

[13]󰀁CuloraGA,MooreIE.Kawasakidisease,Epstein󰀁Barrvirusandcoronaryartery

aneurysm[J].JClinPatho,l1997,50(2):161󰀁163.

[14]󰀁BelginUG,NurcanC,SelmanVY,eta.lCytomegalovirusinfectioninapatient

withatypicalKawasakidisease[J].JRheumatolIn,t2008,28(4):387󰀁389.

[15]󰀁RowleyAH.FindingthecauseofKawasakidisease:apediatricinfectiousdisea󰀁

sesresearchpriority[J].JInfectDis,2006,194:1635󰀁1637.

[16]󰀁DominguezSR,AndersonMS,GlodeMP,eta.lBlindedcase󰀁controlstudyoftherelationshipbetweenhumancoronavirusNL63andKawasakisyndrome[J].

JID,2006,194(11):1697󰀁1701.

[17]󰀁ChangLY,ChiangBL,KaoCL,eta.lLackofassociationbetweeninfectionwith

anovelhumancoronavirus(HCoV),HCoV󰀁NH,andKawasakidiseaseinTai󰀁

wan[J].JID,2006,193(1):283󰀁286.

[18]󰀁EbiharaT,EndoR,MaXM,eta.lLackofassociationbetweennewhavencoro󰀁

navirusandKawasakidisease[J].JID,2005,192(7):350󰀁351.

[19]󰀁SopontammarakS,PromphanW,RoymaneeS,eta.lPositiveserologyforDen󰀁

gueviralinfectioninpediatricpatientswithKawasakidiseaseinsouthernThai󰀁

land[J].CircJ,2008,72(3):1492󰀁1494.

[20]󰀁邹先阶.肺炎支原体感染在川崎病及冠脉损害中的作用[J].中国当代医

药,2009,16(19):20󰀁21.

[21]󰀁常󰀁健,李海波,陈银波,等.肺炎支原体与肺炎衣原体在川崎病冠状动脉

病变中的作用[J].临床儿科杂志,2007,25(9):768󰀁770.

[22]󰀁YeungRSM,TheetiologyofKawasakidisease:asuperantigenmediatedprocess

[J].ProgPediatrCardio,l2004,19(10):115󰀁122.

[23]󰀁RowleyAH.TheetiologyofKawasakidisease:aconventionalinfectiousagent

[J].ProgPediatrCardio,l2004,19(9):109󰀁113.

[24]󰀁CheungYF,HuangGY,ChenSB,eta.lInflammatorygenepolymorphismsand

susceptibilitytoKawasakidiseaseandarterialsequelae[J].Pediatrics,2008,

122(3):e608󰀁614.

[25]󰀁刘󰀁颖.川崎病患儿PS、ES、VEGF血清含量变化的研究[J].中国妇幼保

健,2006,21(18):2538󰀁2539.

[26]󰀁KariyazonoH,OhnoT,KhajoeeV,eta.lAssociationofvascularendothelial

growthfactor(VEGF)andVEGFreceptorgenepolymorphismswithcoronary

arterylesionsofKawasakidisease[J].PediatrRes,2004,56(6):953󰀁959.

[27]󰀁NishimuraS,ZaitsuM,HaraM,eta.lApolymorphisminthepromoterofthe

CD14gene(CD14/󰀁159)isassociatedwiththedevelopmentofcoronaryartery

lesionsinpatientswithKawasakidisease[J].JPediatr,2003,143(3):357󰀁

362.

[28]󰀁IkedaK,IharaK,YamaquchiK,eta.lGeneticanalysisofMMPgenepolymor󰀁

phismsinpatientswithKawasakidisease[J].PediatrRes,2008,23(2):182󰀁

185.

[29]󰀁MinamiT,SuzukiH,TakeuchiT,eta.lApolymorphisminplasmaplateletacti󰀁

vatingfactoracetylhydrolaseisinvolvedinresistancetoimmunoglobulintreat󰀁

mentinKawasakidisease[J].JPediatr,2005,147(1):78󰀁83.

[30]󰀁KimJJ,HongSJ,HongYM,eta.lGeneticvariantsintheHLA󰀁Gregionareas󰀁

sociatedwithKawasakidisease[J].HumanImmuno,l2008,69(10):867󰀁871.

收稿日期:2010󰀁05󰀁14󰀁修回日期:2010󰀁06󰀁12

血管紧张素转换酶2研究进展

周明明󰀁综述󰀁陈󰀁明󰀁审校

(重庆医科大学附属第一医院心内科,󰀁重庆󰀁400016)

AdvancesinResearchofAngiotensinConvertingEnzyme2

ZHOUMing󰀁ming,󰀁CHENMing

(DepartmentofCardiology,TheFirstAffiliatedHospitalofChongqingMedicalUniversity,󰀁Chongqing󰀁400016,󰀁China)

文章编号:1004󰀁3934(2010)04󰀁0620󰀁04󰀁󰀁󰀁󰀁󰀁中图分类号:Q555󰀁󰀁󰀁󰀁󰀁文献标识码:A

DOI:10.3969/.jissn.1004󰀁3934.2010.04.037

󰀁󰀁摘要:󰀁血管紧张素转换酶2是一种金属钛酶,它将血管紧张素I、血管紧张素󰀂分别水解为血管紧张素(1~9)及具有血管舒

张、抗增殖的血管紧张素(1~7)。血管紧张素转换酶2参与了肾素󰀁血管紧张素󰀁醛固酮系统中多种肽的代谢过程,与高血压、肾脏